Trial Profile
Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Mediastinal disorders
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 21 Mar 2021 This trial has been Discontinued in Czechia, Germany and France according to European Clinical Trials Database record.
- 25 Jan 2019 This study has been discontinued in Spain.
- 07 Dec 2018 Status changed from recruiting to withdrawn prior to enrolment.